EARS
Get informed when a big investor buys or sells
+ FollowUndervalued by 127.1% based on the discounted cash flow analysis.
| Market cap | $4.21 Million |
|---|---|
| Enterprise Value | $3.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | 1.4 |
| Outstanding Shares | - |
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -10.46 |
| Enterprise Value to EBIT | -1.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal be...